KalVista Pharmaceuticals, Inc.
(NASDAQ : KALV)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -1.09%161.200.7%$1110.11m
MRKMerck & Co., Inc. 1.06%76.290.7%$1019.05m
PFEPfizer Inc. 1.89%36.640.9%$946.21m
ABBVAbbVie, Inc. 1.33%107.511.9%$816.77m
LLYEli Lilly & Co. 0.93%184.301.1%$717.18m
BMYBristol-Myers Squibb Co. 1.16%62.631.0%$716.73m
AZNAstraZeneca Plc 0.89%49.941.2%$452.77m
GSKGlaxoSmithKline Plc 0.49%36.640.2%$184.82m
RPRXRoyalty Pharma Plc 0.88%42.310.2%$172.99m
NVSNovartis AG 0.64%87.550.2%$152.27m
VTRSViatris, Inc. 0.79%13.400.0%$129.73m
RGENRepligen Corp. 0.95%206.106.8%$92.14m
ENTXEntera Bio Ltd. -5.66%3.500.0%$83.80m
CVACCureVac NV -1.68%87.920.0%$67.80m
SNYSanofi 0.75%50.770.2%$62.88m

Company Profile

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.